OTR Therapeutics has emerged from stealth and announced the successful completion of a $100 million Series A financing.  

The round was backed by True Light Capital, a wholly-owned subsidiary of Temasek, LAV, Pfizer Ventures, and Sirona Capital. 

Founded in March 2025, Shanghai-based OTR Therapeutics aims to discover and acquire distinctive assets in preclinical and early clinical stages, and accelerate their development into differentiated, clinically impactful treatments. 

The proceeds of the financing will advance OTR’s pipeline of differentiated programmes that target treatment gaps in immunology & inflammation, oncology, and other disease areas. The funds will also expand the company’s R&D hub capability. 

OTR also announced the acquisition of a preclinical programme with best-in-class potential for neurological diseases with high unmet needs. This is part of the company’s ongoing efforts to identify and advance promising early-stage assets into global clinical development, alongside its internal proprietary discovery programmes. 

“The rapidly evolving global pharmaceutical R&D landscape demands greater novelty, speed and efficiency,” said Dr Zhui Chen, Founder and CEO of OTR Therapeutics. “At OTR, we aim to build a next-generation biotech model that delivers unprecedented R&D and capital efficiency. It enables us to stay agile while remaining rigorously focused on propelling novel, differentiated drug candidates through global clinical translation in a disciplined and efficient manner.”

Diana Turner, Deputy Editor, DDW